Clinical trials located in

Landshut

Landshut city is located in Germany. Currently, 9 clinical trials are being conducted in this city.

Landshut, nestled in Bavaria, Germany, boasts a rich history dating back to 1204. This picturesque city is renowned for its Gothic architecture, exemplified by the St. Martin’s Church, which houses the world’s tallest brick tower. Every four years, Landshut reenacts the medieval wedding of George of Bavaria to Polish princess Jadwiga, attracting thousands. The city’s charm is further enhanced by the Trausnitz Castle, perched above the old town, offering insights into Bavarian ducal life. Landshut seamlessly blends its historical heritage with vibrant cultural life.

  • CT-EU-00029691

    Study on Zibotentan-Dapagliflozin Combo for Cirrhosis Patients

    The ZEAL study is a study conducted in people suffering from cirrhosis, a disease that causes the accumulation of scar tissue in the liver. The study was divided into two parts and aims to determine how helpful and safe a combination of drugs called zibotentan and dapagliflozin is when given to people suffering from this disease. In the first part, drugs will be administered to one group of volunteers and their reaction will be observed. If no significant safety issues arise, the study will proceed to the second part. Here, more people with varying degrees of liver disease will participate. Several things will be checked: improvement in blood pressure in the liver, effect on body weight, use of other medications to store fluid, and changes in body water and fat content.

    • dapagliflozin
    • zibotentan
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Test of Venetoclax and Obinutuzumab on Chronic Lymphocytic Leukemia

    This study involves adults diagnosed with chronic lymphocytic leukemia (CLL), the most common type of blood cancer, who have relapsed after previous treatment. The study looked at a retreatment approach using two drugs: Venetoclax, an oral pill already approved for the treatment of CLL, and Obinutuzumab, a drug given intravenously. Participants will receive both drugs for 6 cycles of 28 days each, followed by Venetoclax alone for an additional 6 to 18 cycles. There will be regular tests and checks to monitor disease activity and any potential side effects. The study will involve around 75 adults from around the world who have previously been treated with Venetoclax in combination with a specific antibody medicine. To measure the success of the study, researchers will closely monitor the reduction in disease symptoms in response to treatment.

    • Obinutuzumab
    • Venetoclax
  • Comparing carfilzomib and ibrutinib for treating Waldenström’s Macroglobulinemia

    This study investigates the effectiveness of combining Carfilzomib with Ibrutinib for treating Waldenström’s Macroglobulinemia (WM), compared to Ibrutinib alone. It focuses on adults with either new or relapsed/refractory WM. The aim is to see if adding Carfilzomib improves response rates, particularly in patients with certain genetic mutations. Participants will be monitored for treatment responses and side effects. This research could provide a more effective treatment option for WM patients, especially those not responding well to current therapies.

    • Cafilzomib
    • Ibrutinib
  • Exploring chronic lymphocytic leukemia treatments: acalabrutinib, obinutuzumab, venetoclax in new trial

    This clinical trial compares two drug combinations for treating high-risk chronic lymphocytic leukemia (CLL). It’s a Phase 3 study, focusing on patients who haven’t received prior treatment. Participants will either receive a triple combination of acalabrutinib, obinutuzumab, and venetoclax (GAVe) or a double combination of obinutuzumab and venetoclax (GVe). The main goal is to see if the triple combination can better prolong the time patients live without their disease getting worse, compared to the double combination.

    • Obinutuzumab
    • Acalabrutinib
    • Venetoclax
  • Breast cancer treatment study: camizestrant vs. standard therapy

    This study is looking at a new drug called camizestrant for adults with a certain type of early breast cancer (ER+/HER2-). It compares camizestrant with standard endocrine therapies like tamoxifen and aromatase inhibitors in patients who have already received 2–5 years of endocrine therapy. The study’s focus is on preventing cancer recurrence over 60 months. About 4300 participants are involved, and the trial features an open-label design, meaning everyone knows which treatment they are receiving. The main goal is to check how well the camizestrant works in comparison to standard treatments.

    • camizestrant
    • Anastrozole
    • Letrozole
    • Exemestane
    • tamoxifen
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in Germany:

.